HTLV-1, immune response and autoimmunity

Viruses

Volumn 8, Issue 1, 2015, Pages

  Quaresma, Juarez A S ^a   Yoshikawa, Gilberto T ^b   Koyama, Roberta V L ^a   Dias, George A S ^a   Fujihara, Satomi ^b   Fuzii, Hellen T ^b  

^a UNIVERSIDADE DO ESTADO DO PARÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Autoimmunity; Human T lymphotropic virus type 1 (HTLV 1); Immune response

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR; ANTINUCLEAR ANTIBODY; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; JANUS KINASE; PROTEIN C JUN; SERUM RESPONSE FACTOR; STAT PROTEIN; TAX PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; CD4+ T LYMPHOCYTE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HUMAN T-LYMPHOTROPIC VIRUS 1; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LONG TERMINAL REPEAT; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; GENETICS; HTLV-1 INFECTION; IMMUNOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; AUTOIMMUNITY; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS;

EID: 84952039931     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v8010005     Document Type: Review

References (93)

1. Von Herrath, M.G.; Fujinami, R.S.; Whitton, J.L. Microorganisms and autoimmunity: Making the barren field fertile? Nat. Rev. Microbiol. 2003, 1, 151-157. [CrossRef] [PubMed]
2. Libbey, J.E.; Fujinami, R.S. Potential triggers of MS. Results Probl. Cell Differ. 2010, 51, 21-42.
3. Fujinami, R.S. Viruses and autoimmune disease-Two sides of the same coin? Trends Microbiol. 2001, 9, 377-381. [CrossRef]
4. McCoy, L.; Tsunoda, I.; Fujinami, R.S. Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity 2006, 39, 9-19. [CrossRef] [PubMed]
5. Sfriso, P.; Ghirardello, A.; Botsios, C.; Tonon, M.; Zen, M.; Bassi, N.; Bassetto, F.; Doria, A. Infections and autoimmunity: The multifaceted relationship. J. Leukoc. Biol. 2010, 87, 385-395. [CrossRef] [PubMed]
6. Araujo, A.Q.; Silva, S.T. The HTLV-1 neurological complex. Lancet Neurol. 2006, 5, 1068-1076. [CrossRef]
7. Gessain, A.; Barin, F.; Vernant, J.C.; Gout, O.; Maurs, L.; Calender, A.; de Thé, G. Antibodies to human T lymphotropicvírus type I in patients with tropical spastic paraparesis. Lancet 1985, 2, 407-410. [CrossRef]
8. Román, G.C.; Osame, M. Identity of HTLV-I-associated tropical spastic paraparesis and HTLV-I-associated myelopathy. Lancet 1988, 1. [CrossRef]
9. Romanelli, L.C.F.; Caramelli, P.; Proietti, A.B.F.C. Human T-cell leukemia virus type 1 (HTLV-1): When do we suspect of infection? Rev. Assoc. Med. Brás. 2010, 56, 340-347. [CrossRef] [PubMed]
10. Cooper, S.A.; van der Loeff, M.S.; Taylor, G.P. The neurology of HTLV-1 infection. Pract. Neurol. 2009, 9, 16-26. [CrossRef] [PubMed]
11. Gessain, A.; Mahieux, R. Tropical spastic paraparesis and HTLV-1 associated myelopathy: Clinical, epidemiological, virological and therapeutic aspects. Rev. Neurol. 2012, 168, 257-269. [CrossRef] [PubMed]
12. Boxus, M.; Willems, L. Mechanisms of HTLV-1 persistence and transformation. Br. J. Cancer 2009, 101, 1497-1501. [CrossRef] [PubMed]
13. Hoshino, H. Cellular factors involved in HTLV-1 entry and pathogenicit. Front. Microbiol. 2012, 3. [CrossRef] [PubMed]
14. Lairmore, M.D.; Anupam, R.; Bowden, N.; Haines, R.; Haynes, R.A., II; Ratner, L.; Green, P.L. Molecular determinants of human T-lymphotropic virus type 1 transmission and spread. Viruses 2011, 3, 1131-1165. [CrossRef] [PubMed]
15. Matsuura, E.; Yamano, Y.; Jacobson, S. Neuroimmunity of HTLV-I Infection. J. Neuroimmune Pharmacol. 2010, 5, 310-325. [CrossRef] [PubMed]
16. + cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population. Immunology 2009, 128, e777-e786. [CrossRef] [PubMed]
17. Marriott, S.J.; Semmes, O.J. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005, 24, 5986-5995. [CrossRef] [PubMed]
18. Grassmann, R.; Aboud, M.; Jeang, K.T. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005, 24, 5976-5985. [CrossRef] [PubMed]
19. Cheng, H.; Ren, T.; Sun, S.C. New insight into the oncogenic mechanism of the retroviral oncoprotein Tax. Protein Cell 2012, 3, 581-589. [CrossRef] [PubMed]
20. Higuchi, M.; Fujii, M. Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis. Retrovirology 2009, 6. [CrossRef] [PubMed]
21. Jeang, K.T. HTLV-1 and adult T-cell leukemia: Insights into viral transformation of cells 30 years after virus discovery. J. Formos. Med. Assoc. 2010, 109, 688-693. [CrossRef]
22. Beimling, P.; Moelling, K. Direct interaction of CREB protein with 21 bp Tax-response elements of HTLV-ILTR. Oncogene 1992, 7, 257-262. [PubMed]
23. Satou, Y.; Yasunaga, J.; Yoshida, M.; Matsuoka, M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl. Acad. Sci. USA 2006, 103, 720-725. [CrossRef] [PubMed]
24. Matsuoka, M. Human T-cell leukemia virus type I (HTLV-I) infection and the onset of adult T-cell leukemia (ATL). Retrovirology 2005, 2. [CrossRef] [PubMed]
25. Cabral, F.; Arruda, L.B.; de Araújo, M.L.; Montanheiro, P.; Smid, J.; de Oliveira, A.C.; Duarte, A.J.; Casseb, J. Detection of human T-cell lymphotropic virus type 1 in plasma samples. Virus Res. 2012, 163, 87-90. [CrossRef] [PubMed]
26. Journo, C.; Mahieux, R. HTLV-1 and innate immunity. Viruses 2011, 3, 1374-1394. [CrossRef] [PubMed]
27. + T cells in cerebrospinal fluid from patients with HAM/TSP. Ann. Neurol. 2001, 50, 807-812. [CrossRef] [PubMed]
28. Gallo, R.C. Research and discovery of the first human cancer virus, HTLV-1. Best Pract. Res. Clin. Haematol. 2011, 24, 559-565. [CrossRef] [PubMed]
29. Morgan, O. HTLV-1 associated myelopathy/tropical spastic paraparesis: How far have we come? West Indian Med. J. 2011, 60, 505-512. [PubMed]
30. Ahuja, J.; Lepoutre, V.;Wigdahl, B.; Khan, Z.K.; Jain, P. Induction of pro-inflammatory cytokines by human T-cell leukemia virus type-1 Tax protein as determined by multiplexed cytokine protein array analyses of human dendritic cells. Biomed. Pharmacother. 2007, 61, 201-208. [CrossRef] [PubMed]
31. + T cells in a retrovirus-associated neuroinflammatory disorder. PLoS ONE 2009, 4. [CrossRef] [PubMed]
32. Oliére, S.; Douville, R.; Sze, A.; Belgnaoui, S.M.; Hiscott, J. Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis. Cytokine Growth Factor Rev. 2011, 22, 197-210. [CrossRef] [PubMed]
33. Puccioni-Sohler, M.; Gasparetto, E.; Cabral-Castro, M.J.; Slatter, C.; Vidal, C.M.; Cortes, R.D.; Rosen, B.R.; Mainero, C. HAM/TSP: Association between white matter lesions on magnetic resonance imaging, clinical and cerebrospinal fluid findings. Arq. Neuropsiquiatr. 2012, 70, 246-251. [CrossRef] [PubMed]
34. Saito, M. Immunogenetics and the pathological mechanisms of human T-cell leukemia virustype 1-(HTLV-1-) associated myelopathy/tropical spastic paraparesis (HAM/TSP). Interdiscip. Perspect. Infect. Dis. 2010, 2010. [CrossRef]
35. Shoeibi, A.; Etemadi, M.; Ahmadi, A.M.; Amini, M.; Boostani, R. "HTLV-I Infection" twenty-year research in neurology department of mashhad university of medical sciences. Iran. J. Basic Med. Sci. 2013, 16, 202-207. [PubMed]
36. Satou, Y.; Matsuoka, M. HTLV-1 and the host immune system: How the virus disrupts immune regulation, leading to HTLV-1 associated diseases. J. Clin. Exp. Hematop. 2010, 50, 1-8. [CrossRef] [PubMed]
37. Fuzii, H.T.; Dias, G.A.S.; Barros, R.J.; Falcão, L.F.; Quaresma, J.A. Immunopathogenesis of HTLV-1-assoaciated myelopathy/tropical spastic paraparesis (HAM/TSP). Life Sci. 2014, 104, 9-14. [CrossRef] [PubMed]
38. Azran, I.; Schavinsky-Khrapunsky, Y.; Aboud, M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 2004, 1. [CrossRef] [PubMed]
39. Kibler, K.V.; Jeang, K.T. CREB/ATF-Dependent repression of cyclin A by human T-cell leukemia virus Type 1 Tax protein. J. Virol. 2001, 75, 2161-2173. [CrossRef] [PubMed]
40. Matsumoto, J.; Ohshima, T.; Isono, O.; Shimotohno, K. HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein. Oncogene 2005, 24, 1001-1010. [CrossRef] [PubMed]
41. Wildin, R.S.; Freitas, A. IPEX and FOXP3: Clinical and research perspectives. J. Autoimmun. 2005, 25, 56-62. [CrossRef] [PubMed]
42. Bacchetta, R.; Gambineri, E.; Roncarolo, M.G. Role of regulatory T cells and FOXP3 in human diseases. J. Allergy Clin. Immunol. 2007, 120, 227-235. [CrossRef] [PubMed]
43. + cells in HTLV-1 infection: Inverse correlation with HTLV-1-especific CTL response. Blood 2008, 111, 5047-5053. [CrossRef] [PubMed]
44. + T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-α and guarantee asymptomatic clinical status during chronic HTLV-I infection. Clin. Exp. Immunol. 2007, 147, 35-44. [CrossRef] [PubMed]
45. Santos, S.B.; Muniz, A.L.; Carvalho, E.M. HTLV-1-associated myelopathy Immunopathogenesis. Gaz. Méd. Bahia 2009, 79, 11-17.
46. Palmer, D.C.; Restifo, N.P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 2009, 30, 592-602. [CrossRef] [PubMed]
47. Tamiya, T.; Kashiwagi, I; Takahashi, R.; Yasukawa, H.; Yoshimura, A. Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: Regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 980-985. [CrossRef] [PubMed]
48. Yoshimura, A.; Suzuki, M.; Sakaguchi, R.; Hanada, T.; Yasukawa, H. SOCS, inflammation, and autoimmunity. Front. Immunol. 2012, 12. [CrossRef] [PubMed]
49. Nishiura, Y.; Nakamura, T.; Fukushima, N.; Moriuchi, R.; Katamine, S.; Eguchi, K. Increased mRNA expression of Th1-cytokine signaling molecules in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Tohoku J. Exp. Med. 2004, 204, 289-298. [CrossRef] [PubMed]
50. Araújo, A.Q.; Leite, A.C.; Lima, M.A.; Silva, M.T. HTLV-1 and neurological conditions: When to suspect and when to order a diagnostic test for HTLV-1 infection? Arq. Neuropsiquiatr. 2009, 67, 132-138. [CrossRef] [PubMed]
51. Castro-Costa, C.M.; Araújo, A.Q.; Câmara, C.C.; Ferreira, A.S.; Santos, T.J.; Castro-Costa, S.B.; Alcântara, R.N.; Taylor, G.P. Pain in tropical spastic paraparesis/HTLV-I associated myelopathy patients. Arq. Neuropsiquiatr. 2009, 67, 866-870. [CrossRef] [PubMed]
52. Heraud, J.M.; Merien, F.; Mortreux, F.; Mahieux, R.; Kazanji, M. Immunological changes and cytokine gene expression during primary infection with human T-cell leukaemia virus type 1 in squirrel monkeys (Saimiri sciureus). Virology 2007, 361, 402-411. [CrossRef] [PubMed]
53. high T regulatory cells is inversely correlated with human T lymphotrophic virus type-1 (HTLV-1) proviral load in HTLV-1-infection and HTLV-1-associated myelopathy/tropical spastic paraparesis. BMC Immunol. 2008, 9. [CrossRef] [PubMed]
54. Montes, M.; Sanchez, C.; Verdonck, K.; Lake, J.E.; Gonzalez, E.; Lopez, G.; Terashima, A.; Nolan, T.; Lewis, D.E.; Gotuzzo, E.; et al. Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl. Trop. Dis. 2009, 3. [CrossRef] [PubMed]
55. Santos, S.B.; Porto, A.F.; Muniz, A.L.; Jesus, A.R.; Magalhães, E.; Melo, A.; Dutra, W.O.; Gollob, K.J.; Carvalho, E.M. Exacerbated inflammatory cellular imune response characteristics of HAM/TSP is observed in a large proportionof HTLV-I asymptomatic carriers. BMC Infect. Dis. 2004, 4. [CrossRef]
56. Brito-Melo, G.E.; Martins-Filho, O.A.; Carneiro-Proietti, A.B.; Catalan-Soares, B.; Ribas, J.G.; Thorum, G.W.; Barbosa-Stancioli, E.F. Phenotypic study of peripheral blood leucocytes in HTLV-I-infected individuals from Minas Gerais, Brazil. Scand. J. Immunol. 2002, 55, 621-628. [CrossRef] [PubMed]
57. Coutinho, R.J.; Grassi, M.F.; Korngold, A.B.; Olavarria, V.N.; Galvão-Castro, B.; Mascarenhas, R.E. Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers. BMC Infect. Dis. 2014, 22. [CrossRef] [PubMed]
58. Walker, L.S.; Abbas, A.K. The enemy within: Keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2002, 2, 11-19. [CrossRef] [PubMed]
59. O'Garra, A.; Vieira, P. Regulatory T cells and mechanisms of immune system control. Nat. Med. 2004, 10, 801-805. [CrossRef] [PubMed]
60. Moudgil, K.D.; Choubey, D. Cytokines in autoimmunity: Role in induction, regulation, and treatment. J. Interferon Cytokine Res. 2011, 31, 695-703. [CrossRef] [PubMed]
61. Parks, C.G.; Miller, F.W.; Pollard, K.M.; Selmi, C.; Germolec, D.; Joyce, K.; Rose, N.R.; Humble, M.C. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int. J. Mol. Sci. 2014, 15, 14269-14297. [CrossRef] [PubMed]
62. Cárdenas-Roldán, J.; Rojas-Villarraga, A.; Anaya, J.M. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC. Med. 2013, 73. [CrossRef]
63. Lossius, A.; Johansen, J.N.; Torkildsen, O.; Vartdal, F.; Holmøy, T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis-association and causation. Viruses 2012, 4, 3701-3730. [CrossRef] [PubMed]
64. Getts, D.R.; Chastain, E.M.; Terry, R.L.; Miller, S.D. Virus infection, antiviral immunity, and autoimmunity. Immunol. Rev. 2013, 255, 197-209. [CrossRef] [PubMed]
65. Levin, M.C.; Lee, S.M.; Kalume, F.; Morcos, Y.; Dohan, F.C.; Hasty, K.A.; Callaway, J.C.; Zunt, J.; Desiderio, D.; Stuart, J.M. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat. Med. 2002, 8, 509-513. [CrossRef] [PubMed]
66. García-Vallejo, F.; Domínguez, M.C.; Tamayo, O. Autoimmunity and molecular mimicry in tropical spastic paraparesis/human T-lymphotropic virus-associated myelopathy. Braz. J. Med. Biol. Res. 2005, 38, 241-250. [PubMed]
67. Alamanos, Y.; Voulgari, P.V.; Drosos, A.A. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review. Semin. Arthritis Rheum. 2006, 36, 182-188. [CrossRef] [PubMed]
68. Mota, L.M.H.; Laurindo, I.M.M.; Santos Neto, L.L. Artrite reumatoide inicial-conceitos. Rev. Assoc. Med. Bras. 2010, 56, 227-229. [CrossRef] [PubMed]
69. Coenen, M.J.H.; Gregersen, P.K. Rheumatoid arthritis: A view of the current genetic landscape. Genes Immun. 2008, 77, 1-11. [CrossRef] [PubMed]
70. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 5, 356-361. [CrossRef] [PubMed]
71. Feldmann, M.; Brennan, F.M. Rheumatoid arthritis. Cell 1996, 85, 307-310. [CrossRef]
72. Meyer, P.W.; Hodkinson, B.; Ally, M.; Musenge, E.; Wadee, A.A.; Fickl, H.; Tikly, M.; Anderson, R. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Med. Inflamm. 2010, 2010. [CrossRef] [PubMed]
73. Steiner, G.; Tohidast-Akrad, M.; Witzmann, G.; Vesely, M.; Studnicka-Benke, A.; Gal, A.; Kunaver, M.; Zenz, P.; Smolen, J.S. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology 1999, 38, 202-213. [CrossRef] [PubMed]
74. Nishioka, K.; Nakajima, T.; Hasunuma, T.; Sato, K. Rheumatic manifestation of human leukemia virus infection. Rheum. Dis. Clin. N. Am. 1993, 19, 489-503.
75. Yakova, M.; Lézin, A.; Dantin, F.; Lagathu, G.; Olindo, S.; Jean-Baptiste, G.; Arfi, S.; Césaire, R. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005, 1. [CrossRef]
76. Firestein, G.S.; Zvaifler, N.J. Rheumatoid arthritis: A disease of disordered immunity. In Inflammation: Basic Principles and Clinical Correlates, 2nd ed.; Raven Press Ltd.: New York, NY, USA, 1992; pp. 959-975.
77. Eguchi, K.; Origuchi, T.; Takashima, H.; Iwata, K.; Katamine, S.; Nagataki, S. High seroprevalence of anti-HTLV-1 antibody in rheumatoid arthritis. Arthritis Rheum. 1996, 39, 463-466. [CrossRef] [PubMed]
78. Brzustewicz, E.; Bryl, E. The role of cytokines in the pathogenesis of rheumatoid arthritis-Practical and potential application of cytokines as biomarkers and targets of personalized therapy. Cytokine 2015, 76, 527-536. [CrossRef] [PubMed]
79. Ijichi, S.; Matsuda, T.; Maruyama, I.; Izumihara, T.; Kojima, K.; Niimura, T.; Maruyama, Y.; Sonoda, S.; Yoshida, A.; Osame, M. Arthritis in a human T lymphotropic virus type I (HTLV-I) carrier. Ann. Rheum. Dis. 1990, 49, 718-721. [CrossRef] [PubMed]
80. Fox, R.I.; Tornwall, J.; Maruyama, T.; Stern, M. Evolving concepts of diagnosis, pathogenesis, and therapy of Sjogren's syndrome. Curr. Opin. Rheumatol. 1998, 10, 446-456. [CrossRef] [PubMed]
81. 1s syndrome. Curr. Opin. Rheumatol. 2015, 27, 468-475. [CrossRef] [PubMed]
82. Eguchi, K.; Matsuoka, N.; Ida, H.; Nakashima, M.; Sakai, M.; Sakito, S.; Kawakami, A.; Terada, K.; Shimada, H.; Kawabe, Y. Primary Sjögren's syndrome with antibodies to HTLV-1: Clinical and laboratory features. Ann. Rheum. Dis. 1992, 51, 769-776. [CrossRef] [PubMed]
83. Vernant, J.C.; Buisson, G.; Magdeleine, J.; Thore, J.; Jouannelle, A.; Neisson-Vernant, C.; Monplaisir, N. T-lymphocyte alveolitis, tropical spastic paresis, and Sjogren syndrome. Lancet 1988, 1. [CrossRef]
84. 1s syndrome. Arthritis Rheumatol. 2015, 67, 1096-1106. [CrossRef] [PubMed]
85. Scofield, L.; Alarcón, G.S.; Cooper, G.S. Employment and disability issues in systemic lupus erythematosus: A review. Arthritis Care Res. 2008, 59, 1475-1479. [CrossRef] [PubMed]
86. Cooper, G.S.; Gilbert, K.M.; Greidinger, E.L.; James, J.A.; Pfau, J.C.; Reinlib, L.; Richardson, B.C.; Rose, N.R. Recent advances and opportunities in research on lupus: Environmental influences and mechanisms of disease. Cien. Saude Colet. 2009, 14, 1865-1876. [CrossRef] [PubMed]
87. Tiffin, N.; Adeyemo, A.; Okpechi, I. A diverse array of genetic factors contribute to the pathogenesis of systemic lupus erythematosus. Orphanet J. Rare Dis. 2013, 7. [CrossRef] [PubMed]
88. Yap, D.Y.; Lai, K.N. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: From basics to recent advances. J. Biomed. Biotechnol. 2010, 2010. [CrossRef] [PubMed]
89. Shirdel, A.; Hashemzadeh, K.; Sahebari, M.; Rafatpanah, H.; Hatef, M.; Rezaieyazdi, Z.; Mirfeizi, Z.; Faridhosseini, R. Is there any association between human lymphotropic virus type I (HTLV-I) infection and systemic lupus erythematosus? Iran. J. Basic Med. Sci. 2013, 16, 252-257. [PubMed]
90. Sugimoto, T.; Okamoto, M.; Koyama, T.; Takashima, H.; Saeki, M.; Kashiwagi, A.; Horie, M. The occurrence of systemic lupus erythematosus in an asymptomatic carrier of human T-cell lymphotropic virus type I. Clin. Rheumatol. 2007, 26, 1005-1007. [CrossRef] [PubMed]
91. Akimoto, M.; Matsushita, K.; Suruga, Y.; Aoki, N.; Ozaki, A.; Uozumi, K.; Tei, C.; Arima, N. Clinical manifestations of human T lymphotropic virus type I-infected patients with systemic lupus erythematosus. J. Rheumatol. 2007, 34, 1841-1848. [PubMed]
92. Magistrelli, C.; Samoilova, E.; Agarwal, R.K.; Banki, K.; Ferrante, P.; Vladutiu, A.; Phillips, P.E.; Perl, A. Polymorphic genotypes of the HRES-1 human endogenous retrovirus locus correlate with systemic lupus erythematosus and autoreactivity. Immunogenetics 1999, 49, 829-834. [CrossRef] [PubMed]
93. Olsen, R.G.; Tarr, M.J.; Mathes, L.E.; Whisler, R.; du Plessis, D.; Schulz, E.J.; Blakeslee, J.R. Serological and virological evidence of human T-lymphotropic virus in systemic lupus erythematosus. Med. Microbiol. Immunol. 1987, 176, 53-64. [CrossRef] [PubMed]